Focus: GSK is a London-based Big Pharma with 70,000 employees specializing in small molecules, vaccines, and biologics across vaccines, infectious disease, HIV/AIDS, oncology, and immunology. The company operates as a mature, publicly traded entity with a diversified but heavily concentrated product portfolio.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Hot — 877 jobs added in 30d
Net +146 (877 new, 731 removed). Aggressive expansion phase.
2 recent layoff filings (12 mo) — 300 affected
Source: state DOL filings via Big Local News
GSK offers stability, scale, and commercial opportunity today, but the massive patent cliff and recent layoffs create medium-term career risk; best for those comfortable with restructuring cycles or seeking 3–5 year commercial roles before transition.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for GSK
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from GSK's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Flagship triple-therapy inhaler representing 44% of company revenue; critical revenue driver through 2031 but faces steep decline post-LOE.
Dual-therapy respiratory asset with same LOE date as TRELEGY; second-largest revenue contributor in portfolio.
Dual-therapy LAMA/LABA inhaler facing patent expiry in late 2030; third-largest contributor to respiratory franchise.
Monotherapy LAMA with earliest LOE date in portfolio (December 2027); erosion risk is imminent and acute.
Legacy dual-therapy ICS/LABA with uncertain LOE; still generating significant revenue despite competitive pressure from newer inhalers.
Monotherapy ICS facing patent expiry in August 2026; first major LOE event in portfolio creates near-term headwind.
181 discontinued, 48 duplicate formulations not shown
+18 more products with revenue data
GSK plc Stock (GB0009252882): Oncology expansion and Nuvalent deal put focus on valuation - AD HOC NEWS
GSK plc Stock (GB0009252882): Oncology expansion and Nuvalent deal put focus on valuation AD HOC NEWS
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion - TradingView
Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion TradingView
GSK Makes $10.6 Billion Oncology Bet With Nuvalent Acquisition to Accelerate Cancer Expansion (GSK) - Yahoo Finance UK
GSK Makes $10.6 Billion Oncology Bet With Nuvalent Acquisition to Accelerate Cancer Expansion (GSK) Yahoo Finance UK
GSK Strikes $10.6 Billion Deal for Nuvalent in One of Pharma's Biggest Oncology Acquisitions of 2026 - CHEManager
GSK Strikes $10.6 Billion Deal for Nuvalent in One of Pharma's Biggest Oncology Acquisitions of 2026 CHEManager
Wave of Biotech Acquisitions: Eli Lilly, Vidac Pharma, and GSK in the Spotlight - news.financial
Wave of Biotech Acquisitions: Eli Lilly, Vidac Pharma, and GSK in the Spotlight news.financial
Ajay Tandon Joins GSK as Director, Product Management – Field Technology - hrtoday.in
Ajay Tandon Joins GSK as Director, Product Management – Field Technology hrtoday.in
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Recent peer-reviewed publications with author affiliations at this company
+35 more products
Recent layoffs combined with $9.3B patent-cliff exposure create material career-continuity risk; employees should expect further restructuring announcements through 2027–2031 and plan accordingly.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo